Fadraciclib
Fadraciclib (CYC065) is a potent, orally bioavailable inhibitor targeting CDK2 and CDK9 kinases with IC50 values of 5 nM and 26 nM, respectively. It is used in cancer research to study transcriptional regulation and apoptosis, demonstrating activity in both in vitro cell-based assays and in vivo tumor models.
Product Specifications
CAS Number
1070790-89-4
Product Name Alternative
CDK9, CDK, CDK2, Cyclin dependent kinase, CYC 065, CYC065, CYC-065, inhibit, Fadraciclib, Inhibitor
Field of Research
Cell Biology
Purity
98.71% (May vary between batches)
Solubility
DMSO:100 mg/mL (251.56 mM) ;10% DMSO+40% PEG300+5% Tween 80+45% Saline:4 mg/mL (10.06 mM)
Smiles
CC[C@H] (Nc1nc (NCc2cnc (C) cc2C) c2ncn (C (C) C) c2n1) [C@@H] (C) O
Molecular Formula
C21H31N7O
Molecular Weight
397.52
Storage Conditions
Pure form: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.
Notes
For research use only.
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
Lipoprotein lipase Rabbit Polyclonal Antibody (Cy5.5)
C11orf82 (DDIAS) (NM_145018) Human Over-expression Lysate
